Thus, in the prospective multicenter Phase-3 trial that led to the approval of the radiopharmaceutical [68Ga]Ga-PSMA-11, Hope et al. [35] found that in 277 patients with high-risk PC with PET/CT with [68Ga]Ga-PSMA-11 before prostatectomy, 27% of patients had a positive result for pelvic lymph node metastases with a sensitivity of 40%, a specificity of 95%, a positive predictive value of 75% and a negative predictive value of 81%. This evidence concerns the gene FOLH1 and pachyonychia congenita.